Parkdale

Researchers are conducting a phase II randomized, placebo-controlled trial to study the effects of oral N-Acetylcysteine (NAC) in adults who carry the Huntington disease gene expansion but do not yet show clear motor symptoms. The study aims to evaluate clinical and brain imaging outcomes over a period of up to three years to better understand NAC's potential impact on disease progression in this premanifest stage. Participants are randomly assigned to receive either 1 gram of clinical grade NAC capsules or matching placebo capsules, taken orally twice daily. The trial includes detailed monitoring through clinical assessments and magnetic resonance imaging (MRI) scans to track changes in brain structure, particularly focusing on the rate of caudate atrophy. The study also measures the rate at which participants develop motor symptoms indicative of Huntington disease over the three-year period. Throughout the study, participants will undergo regular clinical evaluations and MRI scans to monitor neurological changes and motor function. Researchers will collect data on caudate atrophy rates and motor symptom development to assess treatment effects. Safety and tolerability are closely observed, with ongoing assessments to ensure participant well-being during the study's duration of up to three years.